本文選題：慢性乙型肝炎 + 治療性疫苗��； 參考：《蘭州大學(xué)》2006年碩士論文

【摘要】：慢性乙型肝炎是一種嚴(yán)重危害人類健康的全球性疾病,目前尚無(wú)有效的藥物進(jìn)行治療,疫苗仍然是預(yù)防乙肝的重要手段。目前普遍使用的乙型肝炎疫苗是以乙肝表面抗原蛋白為基礎(chǔ)的,此類疫苗可誘導(dǎo)人體產(chǎn)生保護(hù)性抗體,從而起到預(yù)防乙型肝炎的作用。但此類疫苗最大的缺點(diǎn)是不能誘導(dǎo)有效的細(xì)胞免疫,而細(xì)胞免疫在清除細(xì)胞內(nèi)病毒,以及打破慢性乙肝患者持續(xù)的免疫耐受狀態(tài)具有極其重要的作用。 本研究對(duì)由中國(guó)預(yù)防醫(yī)學(xué)科學(xué)院病毒學(xué)研究所構(gòu)建的HBV(中國(guó)流行株)核心抗原與PreS1融合重組質(zhì)粒(CS1)進(jìn)行了轉(zhuǎn)導(dǎo)、培養(yǎng)、誘導(dǎo)表達(dá),并對(duì)誘導(dǎo)表達(dá)的條件進(jìn)行了優(yōu)化。通過(guò)表達(dá)產(chǎn)物的SDS-PAGE電泳、western檢測(cè)和抗原性鑒定,確定該蛋白理化、生物學(xué)特性與理論結(jié)果一致。對(duì)表達(dá)的HBV融合蛋白CS1使用DEAE-Sepharose 4FF離子交換和Sephadex-G75分子篩進(jìn)行了兩步層析純化得到了純度達(dá)到98%以上,抗原性較好,免疫原性較強(qiáng)的蛋白。 將純化后的HBV融合蛋白CS1與蘭州生物制品研究所疫苗三室生產(chǎn)的CHO-乙型肝炎表面抗原(HBsAg)聯(lián)合,以不同劑量免疫BALB/C小鼠,并用兩疫苗單獨(dú)免疫作為參照,以生理鹽水作為對(duì)照。免疫后于不同時(shí)間采血ELISA方法檢測(cè)小鼠血清抗體;制備脾臟單個(gè)核細(xì)胞(MNC),做MTT檢測(cè);用血清抗體效價(jià)和淋巴細(xì)胞增殖情況兩種標(biāo)準(zhǔn)確定最優(yōu)劑量和最佳免疫程序。用合適劑量的HBcAg與HBsAg聯(lián)合(CS1+S)后,以終濃度為1mg/ml Al(OH)3作為佐劑與不含佐劑的CS1+S抗原組同時(shí)免疫BALB/C小鼠,并用兩種疫苗單獨(dú)免疫(含和不含Al(OH)3)作為參照,以生理鹽水作為對(duì)照。免疫后用ELISA方法測(cè)定抗體產(chǎn)生的滴度;制備脾臟單個(gè)核細(xì)胞(MNC),ELISA法檢測(cè)細(xì)胞因子IFN-γ分泌水平;應(yīng)用流式細(xì)胞儀分析T細(xì)胞亞群;最后應(yīng)用DTH試驗(yàn)檢測(cè)抗原引起的BALB/C小鼠遲發(fā)型超敏反應(yīng)。最后的結(jié)果顯示HBcAg與HBsAg聯(lián)合免疫小鼠產(chǎn)生的IFN-γ量與二者單獨(dú)免疫相比有顯著性差異(P0.05),CD~(3+)CD~(4+)水平與后者相比顯著增高(P0.05);含Al(OH)_3佐劑的聯(lián)合疫苗CD8~+水平比空白對(duì)照組有顯著性差異(P0.05);聯(lián)合疫苗產(chǎn)生的保護(hù)性抗體anti-HBs與2倍劑量的HBsAg單獨(dú)免疫相比無(wú)顯著性差異(P0.05);含Al(OH)_3佐劑與不含佐劑的抗原免疫效果差異不顯著(P0.05)。 總之,本課題工作表明,用CS1與HBsAg聯(lián)合,具有良好的體液免疫與細(xì)胞免疫效果,有助于清除HBV病毒并有希望打破HBV感染引起的慢性乙型肝炎病人持續(xù)
[Abstract]:Chronic hepatitis B (CHB) is a global disease that seriously endangers human health. There are no effective drugs to treat chronic hepatitis B. Vaccine is still an important method to prevent hepatitis B. Hepatitis B vaccine, which is widely used at present, is based on hepatitis B surface antigen (HBsAg) protein, which can induce human body to produce protective antibody and thus play a role in the prevention of hepatitis B. But the biggest drawback of this kind of vaccine is that it can not induce effective cellular immunity which plays an extremely important role in clearing the intracellular virus and breaking the persistent immune tolerance in patients with chronic hepatitis B. In this study, the recombinant plasmid of HBV core antigen and PreS1 fusion recombinant plasmid constructed by Institute of Virology, Chinese Academy of Preventive Medical Sciences, was transduced, cultured and expressed, and the conditions of induced expression were optimized. The protein was determined by SDS-PAGE electrophoresis and antigenicity identification. The physicochemical and biological properties of the protein were in agreement with the theoretical results. The expressed HBV fusion protein CS1 was purified by DEAE-Sepharose 4FF ion exchange and Sephadex-G75 molecular sieve by two-step chromatography. The purified HBV fusion protein CS1 was combined with CHO- hepatitis B surface antigen HBsAg produced by Lanzhou Biological products Research Institute. BALB / C mice were immunized with different doses. After immunization, serum antibodies were detected by Elisa method at different time points, MNCX was prepared from spleen mononuclear cells, and MTT assay was performed. The optimal dose and the best immune procedure were determined by two criteria: serum antibody titer and lymphocyte proliferation. BALB / C mice were immunized with appropriate dose of HBcAg and HBsAg combined with CS1 S with final concentration of 1mg/ml Albumin OH3 as adjuvant and CS1 S antigen without adjuvant. The mice were immunized with two kinds of vaccines alone (including and without Albumin OH3) as control and physiological saline as control. After immunization, the titer of antibody was determined by Elisa, the level of cytokine IFN- 緯 was detected by Elisa, the T cell subsets were analyzed by flow cytometry. Finally, DTH test was used to detect delayed type hypersensitivity induced by antigen in BALB / C mice. The results showed that the level of IFN- 緯 produced in mice immunized with HBcAg and HBsAg was significantly higher than that in mice immunized with HBcAg and HBsAg alone. There was no significant difference between the protective antibody anti-HBs produced by the combined vaccine and the 2 times dose of HBsAg alone (P 0.05), and there was no significant difference in the immune effect between the adjuvant containing Albumin and the antigen without the adjuvant (P 0.05). In conclusion, the work of this study shows that the combination of CS1 and HBsAg has good humoral and cellular immune effects, which is helpful to eliminate HBV virus and hopefully break the persistence of chronic hepatitis B patients caused by HBV infection.
【學(xué)位授予單位】：蘭州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2006
【分類號(hào)】：R392;Q789

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 駱利敏,李明,夏虎,黃建生,陳百虹,王萍;乙型肝炎病毒多表位治療性抗原基因的合成、表達(dá)及抗原性研究[J];第一軍醫(yī)大學(xué)學(xué)報(bào);2003年08期

2 聞?dòng)衩?何麗芳,瞿滌,馬張妹,姚忻;重組治療性乙型肝炎疫苗(YIC)的實(shí)驗(yàn)研究[J];中國(guó)工程科學(xué);1999年01期

3 竇駿;乙型肝炎病毒治療性疫苗實(shí)驗(yàn)研究與探索[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));2000年06期

4 甘慧,王海平,周勇,王全立;乙型肝炎病毒多表位嵌合蛋白的表達(dá)、純化和鑒定[J];軍事醫(yī)學(xué)科學(xué)院院刊;2003年01期

5 姚偉,鄭菊梅,孟秀園,蘇慶華,王璽珍;治療性乙肝疫苗研究及療效考核[J];微生物學(xué)免疫學(xué)進(jìn)展;1998年03期

6 傅瑞全,秦靜英,覃志堅(jiān),韋啟后;肝病患者血清幾種細(xì)胞因子檢測(cè)結(jié)果分析[J];右江民族醫(yī)學(xué)院學(xué)報(bào);2002年03期

7 劉民,馬華,李柏青;MTT法檢測(cè)小鼠淋巴細(xì)胞增殖性反應(yīng)探討[J];中國(guó)實(shí)驗(yàn)動(dòng)物學(xué)雜志;1999年03期

8 陳心春,周伯平,李美忠,王召欽,王火生,張斌,唐蔚;乙型肝炎病毒核心抗原與前S1抗原融合蛋白誘導(dǎo)小鼠免疫反應(yīng)的實(shí)驗(yàn)研究[J];中華肝臟病雜志;2003年03期

9 李用國(guó),陳敏,張大志,王志毅,曾維群,石小楓,郭淵,郭樹(shù)華,任紅;自體樹(shù)突狀細(xì)胞疫苗治療慢性乙型肝炎的臨床研究[J];中華肝臟病雜志;2003年04期

10 夏國(guó)偉,姜漢英,夏穗生;國(guó)產(chǎn)雷帕霉素對(duì)小鼠淋巴細(xì)胞增殖和DTH、GVHR的免疫抑制作用[J];中華器官移植雜志;2000年06期

，

本文編號(hào)：2011384